Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using Oramed’s oral insulin NEW YORK , Sept.
Presentation Details: H.C. Wainwright 24th Annual Global Investment Conference Date: Tuesday, September 13, 2022 Time: 3:00 p.m. E.T. Location: Lotte New York Palace, New York, NY The presentation will be viewable starting Tuesday, September 13, 2022, at 3:00 p.m. Eastern time, and will be available for 90 days, through the following link: […]
Fierce Biotech: Oramed phase 2 insulin drug data ‘paint an exciting picture’ in rocky NASH landscape
By Gabrielle Masson Sep 13, 2022 11:20am OramedNASHDiabetesPfizer Oramed Pharmaceuticals has posted encouraging phase 2 results for its oral insulin candidate designed to treat diabetes and non-alcoholic steatohepatitis (NASH). The company now awaits phase 3 readouts for the candidate that holds potential to become the first commercial oral insulin capsule for treating diabetes. The double-blind, placebo-controlled […]